Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Quinagolide (CV 205-502, Sandoz), an octahydrobenzo (g) quinoline, is a new non-ergot dopamine agonist which has specific D2 receptor activity and a long half-life, making it suitable for once-daily treatment. Recent uncontrolled reports have suggested that quinagolide may be successfully used for t...
Main Authors: | Verhelst, J, Froud, A, Touzel, R, Wass, J, Besser, G, Grossman, AB |
---|---|
格式: | Journal article |
语言: | English |
出版: |
1991
|
相似书籍
-
The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
由: Grossman, A, et al.
出版: (1987) -
Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
由: Ciccarelli, E, et al.
出版: (1988) -
Total Synthesis of (±)-Quinagolide: A Potent D2 Receptor Agonist for the Treatment of Hyperprolactinemia
由: Subhash P. Chavan, et al.
出版: (2019-05-01) -
Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
由: Ciccarelli, E, et al.
出版: (1989) -
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis
由: Yanyang Zeng, et al.
出版: (2023-01-01)